WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Institutional investors holding positions in GeneDx Holdings Corp. (NASDAQ: WGS) during the period from April 16, 2025 through May 4, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action.

WGS shares declined $33.42 per share, or 49.20%, closing at $34.51 after the Company disclosed a $31.2 million impairment charge, slashed full-year revenue guidance by approximately $65 million, and revealed that a recent acquisition had failed to deliver promised value. The window to apply for lead plaintiff closes on August 3, 2026.

Pension funds, mutual funds, endowments, and other institutional holders of WGS common stock face distinct considerations when a securities class action is filed. With over 29.69 million shares outstanding, institutional holders likely represented a significant portion of the float during the Class Period. Portfolios that acquired shares at prices approaching the Class Period high of $167.52 face potential per-position losses that may trigger fiduciary review obligations under governing plan documents and applicable regulations.

For ERISA-governed plans that held WGS in participant-directed accounts or managed portfolios, the corrective disclosure on May 4, 2026 may require affirmative evaluation of recovery options. Plan fiduciaries have an obligation to investigate potential claims that could benefit plan participants and beneficiaries

The lead plaintiff role provides institutional investors with direct oversight of litigation strategy, settlement terms, and counsel selection